OncoGenex - Riesige Produktpipeline - TOP !
Seite 28 von 36 Neuester Beitrag: 24.04.21 23:08 | ||||
Eröffnet am: | 24.03.15 18:27 | von: Barica Inves. | Anzahl Beiträge: | 882 |
Neuester Beitrag: | 24.04.21 23:08 | von: Ulrikemvfpa | Leser gesamt: | 204.141 |
Forum: | Hot-Stocks | Leser heute: | 88 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 25 | 26 | 27 | | 29 | 30 | 31 | ... 36 > |
Hatte auch eine Email von Oncogenex IR dazu erhalten...in der Zusammenfassung sagte Hershel Berry einfach nur, dass es nichts ungewöhnliches ist, wenn kleine Firmen plötzlich die Chance wittern, irgendwo für Aktionärsrechte zu kämpfen bei solche Healthcare Mergern.
so wie Trash es schon schreibt, ist es mittlerweile fast schon normal, das bei jedem Absturz nach Fails oder wie jetzt bei OGX Merger, dir direkt die Piranhas am Arsch kleben und auch was abknabbern wollen..
da gibt es genügend Bsp für ;-)
Thanks for the follow-up note. My reaction remains unchanged. Simply put, there is no merit to these allegations and these types of suits brought on by 5th rate attorneys are commonplace in the healthcare sector whenever there is a transaction or clinical result. Therefore, I'm not pro issuing a press release on this matter as it can give credence to an issue that is baseless and does not warrant attention. In terms of cash on hand, I don't know the exact amount of cash on hand post merger. I'm certain the Company will update the market in accordance with regulatory guidelines.
Er weiß nicht was in der Kasse ist, ist sich aber sicher das alles ok ist.
Und das sich Anwälte immer etwas aus der Nase ziehen und es keinen Kommentar bedarf, ist nicht Usus.
Ich könnte mich hier wohlfühlen !
Mir gings eher um dieses manipulative Geste Monteverde & Associates PC ... unud da hat er schon recht. Denen sollte man nicht auch noch eine glaubwürdige Plattform liefern.
Trash mein bester, ändere bitte deinen Alias, nicht das noch der Name Programm wird !
Holen wir uns hier unserer Doddsche Spende zurück ?
Werde mich mal einlesen, oder einer Haut mal kurz eine Zusammenfassung rein !
Genex ? Muss Export von Golf und Mazda sein ! Liege ich da richtig ?
https://www.deutsche-apotheker-zeitung.de/daz-az/...aucherentwoehnung
http://www.pharmazeutische-zeitung.de/index.php?id=55734
https://progressofself.wordpress.com/2016/03/17/...erfahrungsbericht/
Treatment failure attributed to resistance is a major problem in medical oncology.
Across tumor types, the majority of patients with cancer are likely to face treatment resistance at some point.
Learn More
Subscribe to news feed
Share
.
Recent News
Wednesday, Mar 8 2017
Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco...
Continue reading
Wednesday, Mar 1 2017
Achieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the National Institutes of Health to Advance the...
Continue reading
Thursday, Feb 23 2017
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2016
Continue reading
See More Recent News
Exploring New Compounds to Meet the Challenge of Cancer Treatment Resistance
OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.
Learn more about cancer treatment resistance.
Product Pipeline
Custirsen (OGX-011) Phase 3
OncoGenex’ lead compound, custirsen, is an experimental drug designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. Clusterin is upregulated in tumor cells in response to treatment interventions such as chemotherapy, hormone ablation and radiation therapy and has been found to be overexpressed in a number of cancers, including prostate, lung, breast and bladder. Increased clusterin production has been linked to faster rates of cancer progression, treatment resistance and shorter survival duration.
Information:For PatientsFor PhysiciansFor Investors
Apatorsen (OGX-427) Phase 2
Apatorsen is a once-weekly intravenous (IV) experimental drug designed to inhibit the production of heat shock protein 27 (Hsp27), a protein that is elevated in many cancers and that has been shown to promote cancer cell growth and tumor metastasis. By inhibiting Hsp27, apatorsen may disable cancer cells’ defenses and overcome treatment resistance. Both the potential single-agent activity and synergistic activity of apatorsen with cancer treatments may increase the overall benefit of existing therapies and augment the durability of treatment outcomes, which could lead to increased patient survival.
Information:For PatientsFor PhysiciansFor Investors
Werde mal die Link's lesen.
http://www.prnewswire.com/news-releases/...uarter-2017-300457033.html
Hello,
you announced the First Quarter 2017 Financial Results today with an Apatorsen update.
My question: Are you in negotiations to monetize this asset ? What are your plans ?
-------------
Yes, as you can imagine, the Company is exploring all possible options to monetize the asset. Warm regards, Hershel
https://arznei-news.de/apatorsen/
20 % Reduktion des Sterberisikos ist schon eine Hausnummer und das bei vergleichbarem Sicherheitsprofil im Vergleich zu Docetaxel.
Alles vor dem Hintergrund der Jubelposts über den Merger ...